Harbour BioMed Partners with Bristol Myers Squibb for $1.1 Bln Deal on Next-Gen Antibodies

Harbour BioMed has partnered with Bristol Myers Squibb for a multi-year, global strategic collaboration to develop next-generation multi-specific antibodies. The deal is worth over $1.1 billion, with Harbour BioMed eligible to receive $90 million upfront and up to $1.035 billion in milestone payments. The partnership will accelerate multi-specific antibody discovery programs and includes tiered royalties.